Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis

3 days ago · Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and …

$43.33
OFF

Arrowhead Pharmaceuticals (ARWR) Stock Forecast & Price Target

2 weeks from now

5 days ago · According to the 10 analysts' twelve-month price targets for Arrowhead Pharmaceuticals, the average price target is $43.33. The highest price target for ARWR is …

marketbeat.com

$18.91
OFF

Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) …

2 weeks from now

1 day ago · Shares of ARWR opened at $18.91 on Friday. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 2.06. The stock has a market cap of $2.35 …

etfdailynews.com

450%
OFF

Arrowhead: A Critical Year Ahead That May Reward Patient Investors

2 weeks from now

May 19, 2020 · Although latecomers to the Arrowhead (NASDAQ:ARWR) story may have been disappointed when, after delivering astonishing ~450% gains in 2019, the company's stock …

seekingalpha.com

$0.05
OFF

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded By

2 weeks from now

Dec 20, 2024 · Arrowhead Pharmaceuticals Stock Down 0.3 %. Shares of ARWR stock traded down $0.05 during mid-day trading on Friday, hitting $19.45. 4,010,988 shares of the stock …

marketbeat.com

50%
OFF

Arrowhead Pharmaceuticals Inc (ARWR) Stock Price, Quote, AI …

2 weeks from now

3 days ago · ARWR: AI Stock Analysis of Arrowhead Pharmaceuticals Inc, including Stock Price, Stock Chart, Technical, Fundamental, Sentiment Analysis and more. Start now and save 50% …

danelfin.com

75%
OFF

Arrowhead Pharmaceuticals (ARWR) P/E Ratio - Public.com

2 weeks from now

The P/E ratio for Arrowhead Pharmaceuticals (ARWR) is -3.78 as of Jan 13, 2025.This represents a decrease of-40.75% compared to its 12-month average P/E ratio of-6.38.A higher P/E ratio …

public.com

$599.49
OFF

Arrowhead Pharmaceuticals (ARWR) Earnings Date And Reports 2025

2 weeks from now

1 day ago · Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a recorded net income of -$599.49 million. ARWR has generated -$5.02 earnings per share over the last four quarters. ...

marketbeat.com

FAQs about Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis Coupon?

How much does Arrowhead Pharmaceuticals (Arwr) cost?

ARWR Arrowhead Pharmaceuticals, Inc. Stock Price & Overview Follow $21.052.26(+12.03%)4:00 PM 11/26/24 NASDAQ |$USD |Post-Market:$21.55+0.50(+2.37%)7:59 PM Summary Ratings Financials Earnings Dividends Valuation Growth Profitability Momentum Peers Options Charting All Analysis Comments News Transcripts SEC Filings Press Releases Related Analysis ...

Is Arrowhead Pharmaceuticals (Arwr) a good stock to buy?

ARWR is trading within a range we consider fairly valued. Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. ...

How far is Arrowhead Pharmaceuticals stock from the 52-week high?

According to the current price, Arrowhead Pharmaceuticals is 49.38% away from the 52-week high. What are analysts forecasts for Arrowhead Pharmaceuticals stock? The 40 analysts offering price forecasts for Arrowhead Pharmaceuticals have a median target of 58.18, with a high estimate of 90.00 and a low estimate of 27.00. ...

Should you buy Arrowhead Pharmaceuticals (Arwr) in 2024?

In 2024, Arrowhead Pharmaceuticals's revenue was $3.55 million, a decrease of -98.52% compared to the previous year's $240.74 million. Losses were -$599.49 million, 192.0% more than in 2023. According to 12 analysts, the average rating for ARWR stock is "Buy." ...

Should you buy Arwr (Arwr) stock?

Losses were -$599.49 million, 192.0% more than in 2023. According to 12 analysts, the average rating for ARWR stock is "Buy." The 12-month stock price forecast is $42.7, which is an increase of 95.42% from the latest price. ...

How did Arrowhead Pharmaceuticals (Arwr) perform in a quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) posted its quarterly earnings data on Thursday, August, 8th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($0.58) by $0.80. The business's quarterly revenue was down 100.0% compared to the same quarter last year. ...